newsfilter
← Latest News
GlobeNewswire·

Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech's Natrunix™ Anti-Cancer Therapy in Pancreatic Cancer

AUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) ("XBiotech") today announced that Benjamin Musher M.D., will chair XBiotech's clinical program for pancreatic cancer. The Company is developing a novel cancer drug, Natrunix